U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

Cureverse Inc. and Angelini Pharma SpA signed a potential $360 million deal for CV-01, an oral small-molecule candidate for ...

A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...

Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 568.82% and ...

Italy’s Angelini Pharma has signed a $360 million biobucks pact centered on a phase 1-stage brain health drug from South ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketamine analog, Ketamir-2, has shown greater pain ...

Neurosteer's high-tech EEG brain scan enables a fast, automatic, music-driven, audio-guided test people can take during their ...

The FDA stated its concerns over patients using compounded GLP-1s for weight loss earlier this year. Compounded drugs are not FDA approved, and the agency warned consumers about adverse events related ...

Wendy has walked up the steps of our nation's capitol 14 times to advocate for Alzheimer's funding. "As we walk in, it's like ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...